Lindbrook Capital, LLC Glycomimetics Inc Transaction History

Lindbrook Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	BUY	$0.54 - $1.15 $1,080 - $2,300	2,000 New	2,000 $1,000
Q4 2021 Jan 18, 2022	SELL	$1.44 - $2.14 $7,200 - $10,700	-5,000 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$1.8 - $2.39 $9,000 - $11,950	5,000 New	5,000 $11,000

25.6M

1.94M

153K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $8.91M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.